Genetic Determinants of Kawasaki Disease

Status Active, not recruiting

Clinical Trial Summary

Kawasaki disease (KD) is an acute self-limited vasculitis of infancy and early childhood. Most patients recover without sequelae although the inflammatory process causes permanent damage to the coronary arteries in 20-25% of untreated children. An infectious aetiology is suspected, but the causative agent has not been identified. The investigators aim to identify the genes underlying both susceptibility to Kawasaki disease, and the development of coronary artery aneurysms.

Clinical Trial Description

The problem to be addressed; Kawasaki disease is now the most common cause of acquired heart disease in children in Japan and North America. Kawasaki disease arises when genetically predisposed children encounter an as yet unidentified infectious agent which may cause only mild illness or no illness at all in children without the genetic predisposition. Other children may suffer permanent damage to the coronary arteries. Identification of the genes involved will help to improve understanding of the disease, and the development of better treatments. Objective The investigators aim to identify the genes underlying both susceptibility to Kawasaki disease, and the development of coronary artery aneurysms. Design The study will recruit nuclear families (affected child and their biological parents) through participating NHS hospitals or through the records of the UK Kawasaki Support Group. Study size 400 affected children and both biological parents (i.e. 1200 participants) Procedures Informed consent using age appropriate patient/parent/guardian information sheets will be taken from parents (or from children aged 16 and over), assent will be taken from the child under the age of 16 (if appropriate). Children recruited during the acute illness; routine clinical and laboratory data and research samples (blood, urine, throat swab). Children recruited retrospectively; study questionnaire (completed by parents), saliva samples.Saliva samples from parents ;

Study Design

Related Conditions & MeSH terms

Atypical Kawasaki Disease
Kawasaki Disease
Mucocutaneous Lymph Node Syndrome

Clinical Trial Details

NCT number	NCT03861130
Study type	Observational
Source	Imperial College London
Contact
Status	Active, not recruiting
Phase
Start date	February 25, 2013
Completion date	December 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05911386` - Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases
Recruiting	`NCT02951234` - A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease	N/A
Active, not recruiting	`NCT02853266` - Measurement of Antibodies in Adults With a History of Kawasaki Disease	N/A
Active, not recruiting	`NCT04747847` - Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease	Early Phase 1
Withdrawn	`NCT04535518` - Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease	Phase 3
Recruiting	`NCT01917721` - Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease	Phase 2
Recruiting	`NCT04656184` - A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment	Phase 3
Recruiting	`NCT03200561` - A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)	Phase 3
Completed	`NCT01440075` - Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease	N/A
Completed	`NCT02179853` - Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease	Phase 1/Phase 2
Withdrawn	`NCT02980263` - Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease	Phase 2
Enrolling by invitation	`NCT02359643` - Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease	N/A
Recruiting	`NCT04278404` - Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Completed	`NCT00760435` - Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease	Phase 3
Completed	`NCT00841789` - A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease	Phase 2
Not yet recruiting	`NCT05643651` - Rivaroxaban for Children With Giant Coronary Artery Aneurysms After Kawasaki Disease	Phase 4
Recruiting	`NCT02114099` - Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease	Phase 2
Not yet recruiting	`NCT05091229` - A Blood Test to Diagnose Kawasaki Disease
Completed	`NCT01431105` - Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities	Phase 1/Phase 2
Recruiting	`NCT01793168` - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford